ARQT News and Press, Arcutis Biotherapeutics Inc. From 03/14/22

WESTLAKE VILLAGE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 18,900 restricted stock u...

Arcutis Biotherapeutics press release (NASDAQ:ARQT): Q4 GAAP EPS of -$1.42 beats by $0.18. Strong financial position with more than $385M in cash, cash equivalents, and marketable securities. For further details see: Arcutis Biotherapeutics GAAP EPS of -$1.42 beats by $0.18

Received U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adults and adolescents Completed enrollment of the sole pivotal Phase 3 trial of roflumilast foam in seborrheic dermatitis E...

Topline data now anticipated in mid-year 2022, followed by a regulatory submission in first half of 2023 A total of 457 subjects are enrolled in the STRATUM study Seborrheic dermatitis affects 10 million people in the U.S. WESTLAKE VILLAGE, Calif., Feb. 01, 2022 (GLOBE N...

Arcutis Biotherapeutics (NASDAQ:ARQT) has obtained a $225M term loan facility from funds managed by SLR Capital Partners. This additional capital further strengthens Arcutis’ balance sheet in advance of a potential 2022 FDA approval and launch of topical roflumilast cream in plaque pso...

WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it has obtained a $225 million term loan facility...

Arcutis Biotherapeutics (NASDAQ:ARQT) announces the FDA's acceptance for review of its new drug application (NDA) for roflumilast cream for psoriasis in adults and adolescents. The FDA assigned a PDUFA target action date of July 29, 2022. Arcutis’ NDA submission is supported by po...

FDA has set a target action date of July 29, 2022 NDA supported by positive efficacy data from the pivotal Phase 3 DERMIS 1 and DERMIS 2 clinical studies, as well as results from the long-term safety study If approved, roflumilast cream would be the first and only topical PDE4 inh...

Data presented at Revolutionizing Atopic Dermatitis (RAD) Conference Vehicle tested was comparable to the moisturizing cream based on primary endpoint of change in transepidermal water loss (TEWL) from baseline at Day 15 Data provide additional support for ongoing studies of inves...

WESTLAKE VILLAGE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated der...